Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
143 Results for "
metabolic syndromes
" in MedChemExpress (MCE) Product Catalog:
Products (143)
143 Results for "metabolic syndromes" in MCE Product Catalog:
42
42 Publications Verification
Synonyms: Frangula emodin
Category:
Polygonaceae Plants Endogenous metabolite Quinones Human Gut Microbiota Metabolites Microorganisms Rheum palmatum L. Anthraquinones Phenols Polyphenols Disease Research Fields Cancer
Target:
13
13 Cited Publications
Synonyms: TEI 6720; TMX 67
Target:
Research Areas:
Febuxostat (TEI 6720) is a potent, selective and non-purine xanthine oxidase (XO) inhibitor with a Ki value of 0.6 nM. Febuxostat has the potential for the research of hyperuricemia and gout .
10
10 Cited Publications
Cat. No.: HY-P1944
CAS No.: 217082-58-1
Target:
Research Areas:
10
10 Cited Publications
Cat. No.: HY-P1944A
Target:
Research Areas:
9
9 Cited Publications
Target:
Research Areas:
RIPA-56 is a highly potent, selective, and metabolically stable inhibitor of receptor-interacting
protein 1 (RIP1) with an IC50 of 13 nM. RIPA-56 can be used for the treatment of systemic inflammatory response syndrome .
5
5 Cited Publications
Synonyms: (S)-(+)-Abscisic acid; ABA
5
5 Cited Publications
Cat. No.: HY-W018772
CAS No.: 50-69-1
Target:
4
Category:
Human Gut Microbiota Metabolites Polysaccharides Metabolic Disease Plants Compositae Endogenous metabolite Disease Research Fields Sophora tomentosa L. Saccharides
Target:
3
3 Cited Publications
Synonyms: S1P1 agonist 3
Target:
Research Areas:
SAR247799 (S1P1 agonist 3) is an oral activity, selective G-protein-biased sphingosine-1 phosphate receptor-1 (S1P1 ) agonist, with EC50s rang from 12.6 to 493 nM in S1P1-overexpressing cells and HUVECs. SAR247799 can be used for the research of endothelial protection, including type-2 diabetes, metabolic syndrome .
3
Target:
Research Areas:
GSK1940029 (SCD inhibitor 1) is a stearoyl-coa desaturase (SCD) inhibitor extracted from patent WO/2009060053 A1, compound example 16.
2
2 Cited Publications
Target:
Research Areas:
AZ-Dyrk1B-33 is a potent and selective Dyrk1B kinase inhibitor, with an IC50 of 7 nM .
2
2 Cited Publications
Cat. No.: HY-N0515
CAS No.: 945619-74-9
1
Category:
Human Gut Microbiota Metabolites Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields
Target:
1
1 Cited Publications
Synonyms: A 3309; AZD 7806
Research Areas:
Elobixibat (A 3309; AZD 7806) is an orally active, bile acid transporter (IBAT) inhibitor with IC50 values ??of 0.53 nM (human IBAT), 0.13 nM (mouse IBAT), and 5.8 nM (canine IBAT). Elobixibat can lower LDL cholesterol, increase serum GLP-1, promote colonic motility, and has the potential to study metabolic syndrome. Elobixibat can be used in the study of chronic functional constipation (CIC), dyslipidemia, non-alcoholic hepatitis, and liver tumors in the elderly .
1
Target:
Research Areas:
Lumiracoxib is a potent,selective and orally active COX-2 inhibitor with a Ki value of 0.06?μM . Lumiracoxib acts as a nonselective NSAID with?anti-inflammatory, analgesic and antipyretic activities. Lumiracoxib can be used for osteoarthritis and bone cancer research .
1
1 Cited Publications
Cat. No.: HY-N5139
CAS No.: 93685-90-6
Synonyms: Lecithins, egg yolk; Belovo PL 85
Category:
1
1 Cited Publications
Synonyms: A 3309 hydrate; AZD 7806 hydrate
Research Areas:
Elobixibat (A 3309; AZD 7806) hydrate is an orally active, bile acid transporter (IBAT) inhibitor with IC50 values ??of 0.53 nM (human IBAT), 0.13 nM (mouse IBAT), and 5.8 nM (canine IBAT). Elobixibat hydrate can lower LDL cholesterol, increase serum GLP-1, promote colonic motility, and has the potential to study metabolic syndrome. Elobixibat hydrate can be used in the study of chronic functional constipation (CIC), dyslipidemia, non-alcoholic hepatitis, and liver tumors in the elderly .
1
1 Cited Publications
Cat. No.: HY-163358
Target:
Research Areas:
Cardiovascular Disease Neurological Disease Inflammation/Immunology
SLC3037 is a NLRP3 inhibitor which blocks NLRP3 from binding to NEK7 or oligomerization, inhibiting inflammasome caused by MSU and other inflammasome activators. SLC3037 can be used for research of gout, cardiovascular diseases, metabolic syndrome or neurodegenerative diseases .
1
1 Cited Publications
Target:
Research Areas:
PPARγ-IN-2 (Compound 5a) is a PPARγ inhibitor. PPARγ-IN-2 inhibits TG accumulation in 3T3-L1 preadipocytes (EC50: 0.106 μM). PPARγ-IN-2 inhibits high-cholesterol diet (HFC)-induced obesity and related metabolic syndrome, and reduces lipid accumulation in adipose tissue .
1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
